Catamaran Climbs to Record After Profit Forecast: Chicago Mover

Catamaran Corp. (CCT) surged to a record as the pharmacy benefits manager for drugstores boosted its full-year earnings forecast after agreeing to buy competitor Restat LLC for $409.5 million.

The shares rose 9.1 percent to C$59.03 in Toronto, the highest close since trading began in 1984, according to data compiled by Bloomberg. They have climbed 26 percent this year as the Standard & Poor’s/TSX Composite Index increased 1.3 percent.

Catamaran, based in Lisle, Illinois, raised its outlook for adjusted 2013 earnings per share to $1.87 to $1.92, from its May forecast of $1.81 to $1.88. The average of 22 analyst estimates compiled by Bloomberg was $1.84. The company cited the purchase of Milwaukee-based Restat and a 10-year partnership agreement with Cigna Corp. (CI) announced in June.

The acquisition of closely held Restat is expected to add about $650 million a year in drug spending and $45 million of annual earnings before interest, taxes, depreciation and amortization, Catamaran said. The transaction, slated to close in the fourth quarter, will be funded through a revolving credit line and cash on hand, the company said.

Catamaran today also reported second-quarter adjusted earnings of 49 cents a share, beating the 44-cent average of 20 analyst estimates compiled by Bloomberg. Revenue doubled to $3.38 billion, trailing the $3.46 billion average estimate.

To contact the reporter on this story: Eric Lam in Toronto at

To contact the editor responsible for this story: Lynn Thomasson at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.